Announcement of press release of press conference on Sept 28, 2020

Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development

Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)

New Appointment of Compensation Committee Member

TFDA clearance for Phase 1 clinical study for active immunotherapeutic cancer vaccine, OBI-866

TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858

Announcement on the change of representative of corporate director

Announcement on resignation of Audit Committee Member

Announcement on resignation of Compensation Committee Member

Announcement on resignation of independent director